83 results about "Attention deficits" patented technology

The invention discloses an attention deficit hyperactivity disorder recognition system and recognition method, and belongs to the technical field of attention deficit hyperactivity disorder. The data processing module is used for carrying out preprocessing and feature extraction on the acquired electroencephalogram data; a multi-source feature fusion mechanism is firstly used for the extracted original feature data, and then a data enhancement strategy is applied; a multi-source fusion feedback regulation network model is constructed, wherein the model is of a CNN-GRU parallel modeling structure; the training module is used for inputting the enhanced data into a model for training, key hyper-parameters are dynamically adjusted by a performance feedback adjusting mechanism in the training process, and the performance feedback adjusting mechanism is used for dynamically adjusting key training parameters according to the performance of the verification set; and the classification module is used for classifying to-be-detected samples through the trained multi-source fusion feedback regulation network model and outputting a final recognition result. The ADHD electroencephalogram recognition method effectively improves the accuracy, robustness and generalization performance of ADHD electroencephalogram recognition.

An apparatus and a method for controlling a pharmaceutical mixer of a medication for Attention Deficit Hyperactivity Disorder (ADHD) based on an assessment of a mental health state of an adolescent. The method comprises: collecting physical information of a user; verifying survey questions regarding mental health depending on the physical information and real-time brain activity data; forming additional survey questions after having verified the answers and calculating a prediction rate of an appearance of symptoms of a mental illness by using AI models; dynamically selecting the most suitable AI model for mental health assessment; verifying a set of survey questions including a plurality of sub-questions depending on the calculated prediction rate; and; outputting result data by adjusting the prediction rate; and transmitting a control signal to the pharmaceutical mixer for the ADHD medicine based on the assessment of the mental health state.

The invention provides a neural developmental disorder prediction model construction method, system and device and a medium, and the method comprises the steps: obtaining the clinical information of a child patient, the clinical information comprises severity of developmental retardation / dyspepsia, complexity of syndromic neurodevelopmental disorder, autism spectrum disorder, epilepsy, attention deficit hyperactivity disorder, head circumference deformity, brain development deformity, hearing / visual function impairment and related ear-eye development deformity; applying logistic regression analysis to screen out predictive factors significantly related to the positive diagnosis rate of third-generation whole exon genome sequencing in the clinical information; constructing a neural developmental disorder prediction model based on binary logistic regression according to the prediction factor; and verifying the neurodevelopmental disorder prediction model by applying data of the internal verification group and the external verification group so as to evaluate the prediction efficiency of the neurodevelopmental disorder prediction model, so that the probability of obtaining positive diagnosis after the child patient receives trio-WES detection can be accurately evaluated, and the prediction efficiency is remarkably improved.

Disclosed are compounds, and corresponding methods of treatment, that activate myocyte-specific enhancer factor 2 (MEF2) transcriptional activity that are therefore useful in treating deficits in MEF2C activity found in autism spectrum disorder (ASD), intellectual disability (ID), attention deficit and hyperactivity disorder (ADHD), and in diseases characterized by cognitive decline such as Alzheimer's disease (AD), Lewy body dementia (LED), Frontotemporal dementia (FTD), and other forms of dementia, as well as movement disorders such as Parkinson's disease (PD) and parkinsonism from other causes.

The invention relates to the field of medical image analysis and neuropsychiatric disease diagnosis, and particularly discloses a brain network typing diagnosis system and method for attention deficit hyperactivity disorder. Comprising a data acquisition and preprocessing module, a topological feature extraction module, a supervised manifold learning module, a network reconstruction and diagnosis module, a parameter optimization module and a result verification module, continuous homology analysis is performed on a brain region function connection matrix based on an algebraic topology theory, and a brain region topological feature matrix is generated; utilizing supervised manifold learning to map the brain region topological feature matrix to a Riemannian manifold, and calculating a brain region importance weight map based on ADHD phenotypic features as supervised signals; according to the method, the brain network is subjected to subtype specific reconstruction through the curvature flow theory of Riemannian geometry, the topological difference between different subtypes is calculated, accurate typing diagnosis of ADHD is achieved, and the diagnosis accuracy is improved by 15%-20%.

Provided is a Bifidobacterium lactis. The Bifidobacterium lactis is Bifidobacterium animalis subsp. lactis BL-11, and the preservation number of the Bifidobacterium animalis subsp. lactis BL-11 is CGMCC No. 20847. The provided Bifidobacterium animalis subsp. Lactis can improve intestine metabolism disorder and normalize the composition of intestine microbiome so as to improve height, suppresses obesity, promote infant and youth physical development and mental development, and prevent and treat mental disorders, said mental disorders including anxiety, depression, attention-deficit / hyperactivity disorder, autism, schizophrenia, hepatic encephalopathy, anorexia, Tourette syndrome, and Asperger syndrome.

The present invention relates a method of treating attention-deficit / hyperactivity disorder (ADHD), wherein the patient suffers from mood disorders and / or anxiety. More specifically, the present invention is directed to a method of using a carbamate compound alone or in combination with other medications, for the treatment of ADHD.

The disclosure relates to, in part, a method of diagnosing whether a patient is afflicted with attention-deficit / hyperactivity disorder (ADHD) and / or selecting ADHD treatment for a patient afflicted with ADHD and / or monitoring response of ADHD symptoms in patient to an ADHD treatment.

The present invention refers to compounds of formula (I). The present invention also relates to compounds of formula (I) for use as G Protein coupled Receptor 139 (GPR139) antagonists in methods of medical treatment of e.g. depression, Alzheimer's disease, schizophrenia, drug addiction, sleep disorders, pain, and attention deficit hyperactivity disorder. Exemplary compounds are e.g. 3-((1H-pyrazol-4-yl)methyl)-6′-(phenyl)-2H-(1,2′-bipyridin)-2-one derivatives and related compounds. The present description discloses the synthesis and characterisation of exemplary compounds, pharmacological data thereof, as well as exemplary tablet formulations comprising the compounds of the invention (e.g. page 83 to page 110; examples 1 to 33; reference example 1; test examples 1 and 2; tables 1 to 4).

Administration of pentadecanoylcarnitine or pentadecanoic acid is provided for prevention, management or treatment of aggression, allergies, allergic rhinitis, Alzheimer's disease, anxiety and anxiety disorders, amyotrophic lateral sclerosis, arthritis, asthma, atherosclerosis, attention-deficit hyperactivity disorder, bipoloar disorder, brain damage, cancer, cardiovascular disease, cholestatic pruritis, depression, chronic obstructive pulmonary disease (COPD), cocaine abuse, cough, dermatitis, depression, drug-seeking behavior, gastrointestinal disorders, facial erythema associated with rosacea, glaucoma, hepatic diseases, hyperactive bladder, hypersensitivity disorders, hypertension, impulsivity, inflammation, mental disorders and conditions, metabolic disorders, migraines, nasal and sinus congestion, nausea, neuropathic pain with and symptoms of multiple sclerosis, neurological and neuropsychiatric disorders, obesity, obsessive-compulsive disorders, opioid-induced respiratory depression, osteoarthritis, pain, Parkinson disease, pathological gambling, peptic ulcers, schizophrenia, sleep disorders, spinal cord injury, tardive dyskinesia, tics and behavioral problems with Tourette's syndrome; as well as for supporting appetite, cardiovascular health, hematologic health, memory, metabolic health, mood, prolonged REM sleep, renal health, sexuality, sociability and metabolic, hematological, renal, and weight loss.

1. The name of the design product: eye movement cognitive and attention assessment training instrument. 2. The use of the design product: for attention deficit groups such as hyperactivity and autism. 3. The design points of the design product: in shape. 4. The picture or photo that best indicates the design points: perspective view 1.

The present invention relates to attention training systems and methods, particularly for treating individuals with Attention-Deficit / Hyperactivity Disorder (ADHD). Specifically, the present invention is related to employing biofeedback and virtual reality technologies to enhance gaze control and attention measures. The claimed invention represents a system and method for attention training that improve the relevant technological field by providing and utilizing a highly informative real-time biofeedback reliably representing the user's ability to sustain attention.

The invention provides psychology attention training equipment, and belongs to the technical field of psychology teaching. Comprising a supporting assembly, a box body assembly is arranged at the upper end of the supporting assembly, a notch is formed in the middle of the front end of the box body assembly, the transverse diameter and the longitudinal diameter of the notch are matched with the transverse diameter and the longitudinal diameter of a displacement assembly, and a mounting assembly is arranged at the upper end of the box body assembly. The I-shaped base, the frame, the square frame and the top box are arranged and spliced into a small compartment with only one entrance and exit, meanwhile, the small compartment is closed in cooperation with the L-shaped frame, follow-up training is conducted in the small compartment, a relatively-closed personal space is provided for students and children who leave the familiar environment and have social terrorism and self-closing, and therefore the students and children can carry out training conveniently and rapidly. According to the invention, interference of an external environment is reduced, a self-adjusting space is reserved, and an obvious social avoidance demand is met, so that the people can relax the mind more easily and reduce anxiety and nervous mood, and thus the people can concentrate on attention deficit training.

Provided are oligomeric agents, oligomeric compounds, methods, and pharmaceutical compositions for reducing the amount or activity of Protocadherin 19 (PCDH19) RNA in a cell or subject, and in certain instances reducing the amount of PCDH19 protein in a cell or subject. Such oligomeric agents, oligomeric compounds, methods, and pharmaceutical compositions are useful to ameliorate at least one symptom or hallmark of a neurodevelopmental disease or disorder. Such neurodevelopmental diseases or disorders include PCDH19 Epilepsy. Such symptoms or hallmarks include seizures, cognitive impairment, intellectual disabilities, autism spectrum disorder, behavioral problems, aggression, anxiety, obsessive-compulsive disorder, hyperactivity, attention deficit disorder (ADD), and attention deficit hyperactivity disorder (ADHD).

The present invention relates to therapeutic compositions and methods for the treatment of attention deficit disorder (ADD), or attention deficit hyperactivity disorder (ADHD). The present invention more particularly relates to a modified-release pharmaceutical formulation designed to improve the delivery and efficacy of central nervous system (CNS) stimulants. The composition consists of a drug-containing core with a CNS stimulant and pharmaceutically acceptable excipients. This core is coated with a sustained-release (SR) layer comprising one or more polymers selected from water-insoluble and water-insoluble pH-dependent polymers, and one or more pharmaceutically acceptable excipients which regulates the gradual release of the drug. Surrounding the SR layer is a delayed-release (DR) outer layer that controls the onset of drug release. This approach aims to enhance symptom control, reduce dosing frequency, and improve patient compliance in the treatment of ADD and ADHD.

The disclosure relates to the use of phosphodiesterase 1 (PDE1) inhibitors for preventing or treating chemobrain, e.g., inhibiting or mitigating one or more symptoms of chemobrain, e.g., feeling of mental fogginess, deficit in attention, disorganized behavior or thinking, confusion, impaired concentration, difficulty finding the right word, difficulty learning new skills, difficulty multitasking, memory impairment (e.g., short-term memory problems, long-term memory problems, impaired verbal memory, impaired visual memory), and / or fatigue.

The present invention relates to the treatment of an executive function disorder, such as attention deficit hyperactivity disorder (ADHD) and / or autism with both lacosamide and oxcarbazepine.

This application relates to a method, apparatus, and device for screening the risk of reading and attention deficit disorder in children. The method includes acquiring multi-channel raw brain blood oxygenation signals under task-induced conditions using a specific layout fNIRS array integrated into a wearable headband, based on a rapid naming cognitive paradigm. Based on the raw brain blood oxygenation signals, a fusion feature vector representing the reading and attention networks is generated by calculating temporal waveform features and frontotemporal functional connectivity strength. The multi-dimensional fusion feature vector is then processed and analyzed using a Transformer classification model to generate classification results indicating the risk level of reading disorders and comorbid ADHD. This application achieves portable and rapid brain function signal acquisition by integrating a targeted fNIRS array with a standardized cognitive paradigm. By fusing temporal dynamics and brain network connectivity features, a multi-dimensional neural representation is constructed. Finally, a lightweight Transformer model is used to output the risk level of reading disorders and comorbid ADHD end-to-end, achieving high-precision automated assisted screening.

The present invention relates to a system and method for real-time screening of Attention Deficit Hyperactivity Disorder using electroencephalographic signals processed through a GPU-accelerated time-frequency inference architecture. The invention enables continuous acquisition of multi-channel electroencephalographic data, adaptive preprocessing for artifact suppression and signal stabilization, and parallel execution of time-frequency transformations to extract neurologically relevant features in real time. Extracted features are analyzed using an inference process configured to identify neurological patterns associated with Attention Deficit Hyperactivity Disorder, while continuous validation of signal quality and temporal consistency ensures diagnostic reliability. The system dynamically adapts analytical parameters based on evolving signal characteristics and regulates computational workload to achieve energy-efficient operation during prolonged monitoring. The invention provides a technically integrated, machine-implemented screening solution capable of delivering reliable, real-time neurological assessment suitable for clinical environments.

The present disclosure discloses an attention system and method for users with attention- deficit / hyperactivity disorder (ADHD), the system (100) comprises a server (102) configured to manage tasks and enable communication between a mobile application (104) and remote devices (106) over a wireless communication medium (108) The system includes a patient identification and registration module (115) for user authentication, a patient input module (116) to collect preferences, and a task presentation module (101) for delivering attention tasks in multiple formats. An automated scoring module (105) tracks performance metrics and provides real-time feedback, while an adaptive module (110) adjusts task complexity based on user performance. The system offers personalized rewards through a motivation module (103), stores user data securely with a data storage module (114), and analyses performance over time with a data analysis module (111). The system is configured for both children and adults, ensuring wide accessibility and engagement.

The present invention relates to therapeutic compositions and methods for the treatment of attention deficit disorder (ADD), or attention deficit hyperactivity disorder (ADHD). The present invention more particularly relates to a modified-release pharmaceutical formulation designed to improve the delivery and efficacy of central nervous system (CNS) stimulants. The composition consists of a drug-containing core with a CNS stimulant and pharmaceutically acceptable excipients. This core is coated with a sustained-release (SR) layer comprising one or more polymers selected from water-insoluble and water-insoluble pH-dependent polymers, and one or more pharmaceutically acceptable excipients which regulates the gradual release of the drug. Surrounding the SR layer is a delayed-release (DR) outer layer that controls the onset of drug release. This approach aims to enhance symptom control, reduce dosing frequency, and improve patient compliance in the treatment of ADD and ADHD.

The invention relates to a pellet as well as a preparation method and application thereof. The pellet has a treatment effect on attention deficit and attention disorder of children. The invention also provides a tablet containing the pellet, the tablet comprises active pharmaceutical ingredients and pharmaceutically acceptable auxiliary materials, and the active pharmaceutical ingredients exist in the core pellet. The pellet and the tablet containing the pellet have a good release characteristic.

The invention discloses an attention enhancement brain-computer interface system based on binocular color competition, and belongs to the technical field of biomedical information. According to the system, electroencephalogram (EEG) data when a user watches a binocular color competition normal form is collected through an electroencephalogram cap, the collected EEG data is classified and recognized by using deep learning, man-machine interaction design is performed by using a neural feedback technology on the basis, adjustment of a neural network of the user is promoted through sound and image modes, and attention enhancement is realized. A new training mode can be provided for the attention deficit patient, and technical support is provided for application of the brain-computer interface technology in the education field.

The present invention refers to compounds of formula (I). The present invention also relates to compounds of formula (I) for use as G Protein coupled Receptor 139 (GPR139) antagonists in methods of medical treatment of e.g. depression, Alzheimer's disease schizophrenia, drug addiction, sleep disorders, pain, and attention deficit hyperactivity disorder. Exemplary compounds are e.g. 1-((1H-pyrazol-4-yl)methyl)-3-(phenyl)-1,3-dihydro-2H-imidazol-2-one derivatives and related compounds. The present description discloses the synthesis and characterisation of exemplary compounds, pharmacological data thereof, as well as exemplary tablet formulations comprising the compounds of the invention (e.g. page 100 to page 143; examples 1 to 167; test examples 1 and 2; tables 1 to 4).

Contemplated test kits, diagnostic apparatus and methods using same for food sensitivity are based on rational-based selection of food preparations with established discriminatory p-value. Kits and diagnostic apparatus include those with a minimum number of food preparations that have an average discriminatory p-value of ≤0.07 as determined by their raw p-value or an average discriminatory p-value of ≤0.10 as determined by FDR multiplicity adjusted p-value. In further contemplated aspects, compositions and methods for food sensitivity are also stratified by gender to further enhance predictive value.

The present invention provides cilnidipine, nilvadipine, isradipine, felodipine, verapamil, nimodipine or nifedipine, or a pharmaceutically acceptable salt or solvate thereof, for use in the treatment or prophylaxis of Attention Deficit / Hyperactivity Disorder (ADHD). The invention also provides kits and methods for the treatment or prophylaxis of ADHD.

The application discloses a game adjusting method and device and a storage medium, and relates to the technical field of games, and can improve the exercise efficiency of attention deficit hyperactivity disorder.

The invention discloses a children attention deficit early intelligent screening system based on multi-modal behavior feature fusion. The system comprises a data acquisition module, a data processing module and a data classification judgment module. The data acquisition module is used for acquiring handwriting data, action feature data and facial expression feature data of a child; the data processing module is used for performing space-time alignment and feature level fusion on the acquired handwriting data, action feature data and facial expression feature data to obtain processed data; and the data classification and judgment module is used for carrying out classification and judgment on the processed data to obtain a screening result and finish early intelligent screening of the attention deficits of children. According to the invention, the Microsoft Surface touch device and the external camera are used for collecting the bottom data in the drawing process of children in real time, and computer vision and a machine learning algorithm are combined, so that the attention defect screening function is realized.

Described herein is the use of nasally-administered oxytocin-based therapeutics to improve cognitive control in individuals with attention-deficit / hyperactivity disorder (ADHD).